oncology
Cancer care

Early & aggressive immunosuppressive therapy needed for irAEs


Additional immunosuppressants should be strongly considered and promptly given when immune-related adverse events (irAEs) associated with cancer immunotherapy aren’t quickly controlled with corticosteroids, Australian researchers say. Based on a case series of patients treated in Adelaide hospitals, they argue that there...

Additional immunosuppressants should be strongly considered and promptly given when immune-related adverse events (irAEs) associated with cancer immunotherapy aren’t quickly...

Read more